New Trial Aims to Speed Breast Cancer Drugs to Market

October 5, 2010


Angela DeMichele, MD, MSCE, as associate professor of Medicine and Epidemiology, and Erica Zado, a physician's assistant in the division of cardiovascular medicine who has been treated for breast cancer in the Abramson Cancer Center, are quoted in a CBS3 story highlighting the I-SPY 2 TRIAL,  unique, new national trial designed to test several experimental, personalized breast cancer drugs at once, with hopes of making them available to more patients sooner. "This study is incredibly exciting because it's really going to change the way we treat breast cancer for every woman who gets the disease," says DeMichele, who is among the national leaders for this trial. "We can get these drugs out to patients sooner. We can find the ones that will work and the ones that won't work in a much more efficient way." Read More

Learn More About the I-SPY 2 Breast Cancer Clinical Trial Available at Penn